MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WHEELER, G. E.
Right arrow Articles by EPAND, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WHEELER, G. E.
Right arrow Articles by EPAND, R. M.

Molecular Pharmacology, Vol 11, 335-339, Copyright © 1975 by the American Society for Pharmacology and Experimental Therapeutics

Prostaglandin E1: Anomalous Effects on Glucose Production in Rat Liver

GRAHAM E. WHEELER 1 and RICHARD M. EPAND 1

1 Department of Biochemistry, Health Sciences Centre, McMaster University, Hamilton, Ontario L8S 4J9, Canada

Prostaglandin E1 decreases the basal rate of glucose production and abolishes the increase usually caused by glucagon or cyclic 3',5'-AMP. This effect is mimicked by insulin, indomethacin, and acetylsalicylate, which also decrease prostaglandin levels. Inhibition of the synthesis of a reactive metabolic intermediate in prostaglandin biosynthesis may explain these apparently anomalous effects.

Note:
ACKNOWLEDGMENT We wish to acknowledge the generous gift of prostaglandins E1 and E2 from Dr. J. Pike of the Upjohn Company.

Submitted on October 10, 1974






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1975 by the American Society for Pharmacology and Experimental Therapeutics